Latest From Humanigen Inc.
US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.
Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.
The latest drug development news and US FDA highlights from our Performance Tracker.
House bill that would require new clinical studies from sponsor for tropical disease priority review vouchers met with industry concerns about limiting the US agency's flexibility.
- Large Molecule
- Therapeutic Areas
- KaloBios Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- Humanigen Inc.
- Senior Management
Cameron Durrant, MD, CEO
Greg Jester, CFO
Niv Caviar, Head, Corp. & Bus. Dev.
Morgan Lam, CSO
- Contact Info
1000 Marina Blvd.
Brisbane, CA 94005
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.